{"disease":{"id":"recurrent-vulvovaginal-candidiasis","name":"recurrent vulvovaginal candidiasis"},"drugs":{"marketed":[{"drug_id":"oteseconazole","indication_name":"Recurrent vulvovaginal candidiasis (RVVC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vivjoa","generic_name":"OTESECONAZOLE","company_name":"Mycovia Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Azole Antifungal [EPC]","quality_score":58,"revenue":null,"mechanism":"Vivjoa works by inhibiting the enzyme Cytochrome P450 3A4, which is involved in the synthesis of ergosterol, a critical component of fungal cell membranes."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04029116","title":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03562156","title":"A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04734405","title":"A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":432,"lead_sponsor_name":"ProFem GmbH","has_results":false},{"nct_id":"NCT03561701","title":"A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT02267382","title":"A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Viamet","has_results":true},{"nct_id":"NCT06190509","title":"Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"LimmaTech Biologics AG","has_results":false},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03840616","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05074602","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":196,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04699240","title":"Study of Lactobacillus in Adjuvant Treatment of RVVC","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Peking University Shenzhen Hospital","has_results":false},{"nct_id":"NCT04639544","title":"Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"Biosearch S.A.","has_results":false},{"nct_id":"NCT05795491","title":"Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Cairo University","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}